Endochondral ossification is the major process of embryonic skeletal development and longitudinal bone growth. During this process chondrocytes within each skeletal element become organized into growth plates and undergo maturation and hypertrophy. Following hypertrophy, the cells reach a final late-hypertrophic stage during which they facilitate cartilage matrix remodeling and mineralization and invasion of blood vessels, leading to replacement of calcified cartilage by bone. This sequence of phenotypic changes requires tight control by numerous systemic and local factors, and alterations of such regulatory mechanisms underlie congenital and acquired skeletal pathologies. The retinoic acid receptors ?, ? and ? (RAR?, RAR? and RAR?) are nuclear hormone receptors that regulate fundamental biological processes. During the previous funding cycle, we studied the roles of RAR signaling in growth plate function and found that (1) RAR? is the dominant receptor in growth plate; (2) expression of RAR? enhances aggrecan production in cultured chondrocytes under retinoid-free condition; (3) RAR? mRNA is predominantly localized in proliferative and prehypertrophic zones but the active form of retinoic acid (atRA) is hardly detectable in these zones; and (4) RAR? deficiency induces skeletal growth retardation. These findings led us to conclude that RAR? exerts an essential role in cartilage matrix production as a ligand-less transcriptional repressor in growth plate. Surprisingly, immuno- histochemical analysis of RAR? revealed that RAR? protein was localized to the hypertrophic zone where atRA was present, indicating that ligand-bound RAR? acts on hypertrophic chondrocytes. We found also that selective RAR? agonists markedly stimulated gene expression levels linked to late-hypertrophic function in cultured primary chondrocytes and that administration of RAR? agonist accelerated chondrocyte hypertrophy and caused growth-plate closure in mouse. These and other findings lead to our central hypothesis that ligand-bound RAR? in hypertrophic zone stimulates late-hypertrophic differentiation of chondrocytes and endochondral ossification and that modulations of RAR? pathway could have therapeutic value. Our specific goals are (1) To define the role of RAR? in regulation of late-hypertrophic differentiation of growth plate chondrocytes and transition from cartilage to bone; (2) To determine the molecular mechanisms by which RAR? regulates late-hypertrophic differentiation of chondrocytes; and (3) To examine the role of RAR? in pathological growth-arrest of long bones and test if selective inhibition of RAR? ameliorates the condition. We will modify RAR? signaling in hypertrophic chondrocytes by use of genetically modified mouse systems and/or pharmacological manipulations and clarify physiological importance of RAR? in growth plate. The results could also provide a new avenue to therapy for precocious growth plate closure and arrest of bone growth which is not currently available for most cases.

Public Health Relevance

The process of skeletal growth during prenatal and postnatal life is critical for establishment of a functioning skeleton and this process is susceptible to congenital or acquired diseases including dwarfism. The mechanisms regulating skeletal growth remain ill defined and understood. This project focuses on nuclear retinoid receptors regulating skeletal cell functions by a multitude of mechanisms, and promises to shed new light into molecular mechanisms of growth that could be exploited therapeutically in the future to correct and restore skeletal growth and function in affected individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
2R01AR056837-07A1
Application #
9026735
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Tyree, Bernadette
Project Start
2008-12-01
Project End
2021-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Uchibe, Kenta; Son, Jiyeon; Larmour, Colleen et al. (2017) Genetic and pharmacological inhibition of retinoic acid receptor ? function promotes endochondral bone formation. J Orthop Res 35:1096-1105
Chakkalakal, Salin A; Uchibe, Kenta; Convente, Michael R et al. (2016) Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation. J Bone Miner Res 31:1666-75
Sinha, Sayantani; Uchibe, Kenta; Usami, Yu et al. (2016) Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent. Bone 90:59-68
Usami, Yu; Gunawardena, Aruni T; Iwamoto, Masahiro et al. (2016) Wnt signaling in cartilage development and diseases: lessons from animal studies. Lab Invest 96:186-96
Pacifici, Maurizio; Shore, Eileen M (2016) Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Cytokine Growth Factor Rev 27:93-104
Di Rocco, Agnese; Uchibe, Kenta; Larmour, Colleen et al. (2015) Selective Retinoic Acid Receptor ? Agonists Promote Repair of Injured Skeletal Muscle in Mouse. Am J Pathol 185:2495-504
Shimono, Kengo; Tung, Wei-En; Macolino, Christine et al. (2011) Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-? agonists. Nat Med 17:454-60
Yasuhara, Rika; Yuasa, Takahito; Williams, Julie A et al. (2010) Wnt/beta-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover. J Biol Chem 285:317-27
Williams, Julie A; Kane, Maureen; Okabe, Takahiro et al. (2010) Endogenous retinoids in mammalian growth plate cartilage: analysis and roles in matrix homeostasis and turnover. J Biol Chem 285:36674-81